- Home
- BARK vs PLX Comparison
BARK vs PLX Comparison
Compare BARK & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BARK
- PLX
- Stock Information
- Founded
- BARK 2011
- PLX 1993
- Country
- BARK United States
- PLX United States
- Employees
- BARK N/A
- PLX N/A
- Industry
- BARK Department/Specialty Retail Stores
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BARK Consumer Discretionary
- PLX Health Care
- Exchange
- BARK Nasdaq
- PLX Nasdaq
- Market Cap
- BARK 146.0M
- PLX 164.2M
- IPO Year
- BARK N/A
- PLX 1998
- Fundamental
- Price
- BARK $0.78
- PLX $2.50
- Analyst Decision
- BARK Strong Buy
- PLX Strong Buy
- Analyst Count
- BARK 3
- PLX 1
- Target Price
- BARK $2.50
- PLX $15.00
- AVG Volume (30 Days)
- BARK 793.3K
- PLX 822.2K
- Earning Date
- BARK 11-06-2025
- PLX 11-13-2025
- Dividend Yield
- BARK N/A
- PLX N/A
- EPS Growth
- BARK N/A
- PLX N/A
- EPS
- BARK N/A
- PLX 0.08
- Revenue
- BARK $470,831,000.00
- PLX $61,948,000.00
- Revenue This Year
- BARK N/A
- PLX $14.53
- Revenue Next Year
- BARK $6.25
- PLX $75.77
- P/E Ratio
- BARK N/A
- PLX $32.28
- Revenue Growth
- BARK N/A
- PLX 62.79
- 52 Week Low
- BARK $0.77
- PLX $0.99
- 52 Week High
- BARK $2.56
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- BARK 37.22
- PLX 75.47
- Support Level
- BARK $0.80
- PLX $1.52
- Resistance Level
- BARK $0.85
- PLX $2.12
- Average True Range (ATR)
- BARK 0.03
- PLX 0.12
- MACD
- BARK -0.01
- PLX 0.05
- Stochastic Oscillator
- BARK 0.11
- PLX 80.97
About BARK BARK Inc.
BARK Inc is a vertically integrated, omnichannel brand serving dogs across two key categories: toys & accessories and consumables. It serves dogs nationwide with monthly subscription services, BarkBox and Super Chewer; e-commerce experience on BarkShop.com; custom collections via its retail partner network, including Target and Amazon; wellness products that meet dogs' needs with BARK Bright; and a personalized meal delivery service for dogs BARK Eats. The company's reportable segments are; Direct to Consumer (D2C), and Commerce. The majority of its revenue is generated from the Direct to Consumer segment which derives revenue from the sale of toys & accessories and consumables through BarkBox, Super Chewer, and the company's consumables website.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.